AAN, AHS Release Updated Migraine Prevention Guidelines for Adults

On August 31, 2026, two major medical organizations—the American Academy of Neurology and the American Headache Society—released updated clinical guidelines for preventing migraine in adults. The document, published simultaneously in Neurology and Headache journals and endorsed by the American Academy of Family Physicians, represents the first significant revision to migraine prevention recommendations since 2012. The update arrives at a moment when the landscape of available treatments has shifted substantially, with newer medication classes now offering alternatives that did not exist when the previous guidelines were written.

Migraine is a chronic neurological condition that extends far beyond a simple headache. During an attack, patients experience not only head pain but also nausea, sensitivity to light and sound, and sometimes dizziness, visual disturbances, or cognitive difficulties. These episodes can stretch from hours to days, and for many people, the impact reaches into every corner of daily life—work becomes impossible, social plans dissolve, routine tasks go undone. The condition is common enough that it drives many patients to neurology clinics, and even more frequently appears in primary care settings, according to Matthew Robbins, president of the American Headache Society.

The new guidelines distinguish between two forms of the disease. Chronic migraine means experiencing headaches on 15 or more days each month, with at least eight of those days carrying the characteristic features of a migraine attack. Episodic migraine involves fewer headache days per month. For both forms, the guidelines recommend offering preventive medication to patients who experience four or more migraine days monthly, or four or more moderate to severe headache days monthly, or whose migraine significantly impairs their ability to work or manage daily responsibilities.

What makes this update particularly significant is the expansion of options available to clinicians and patients. The guidelines cover both established preventive medications and newer treatments that have emerged in recent years. Some medications—antidepressants and blood pressure drugs, for instance—address migraine while simultaneously treating a second health condition a patient may have. Others were designed specifically to target migraine mechanisms. The medications themselves come in different forms: oral pills taken daily or every other day, and injectable treatments administered once monthly or once every three months.

Tamara Pringsheim, one of the guideline authors from the University of Calgary, emphasized that the update reflects careful review of available evidence, with each medication assigned a confidence level regarding its effectiveness. Rebecca Burch, another lead author from the University of Vermont, stressed the practical implication: if one medication class does not work well, another type may succeed. The guideline emphasizes that clinicians should discuss with patients the strength of evidence behind each option, potential side effects, costs, and the practical differences between medication types.

The selection process itself requires attention to the individual patient's circumstances. Clinicians are instructed to assess how migraine is affecting each person's quality of life and to involve patients in shared decision-making about which preventive approach to pursue. Once a patient begins a new medication, the guidelines provide recommended timeframes for reassessing whether the treatment is actually working.

Natalia Rost, president of the American Academy of Neurology, framed the update as part of the organization's broader mission to improve care for people with neurological conditions. Robbins noted that newer treatment options have already transformed care for millions of people across the United States and globally. The guideline itself was funded by the American Academy of Neurology, and its release signals a commitment to keeping clinical practice aligned with current evidence as the field of migraine treatment continues to evolve.